BFM
OCUL icon

Boothbay Fund Management’s Ocular Therapeutix OCUL Stock Holding History

Boothbay Fund Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-54,200
Closed -$502K – 729
2017
Q2 		$502K Buy
+54,200
New +$525K 0.1% 234

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Boothbay Fund Management's OCUL Position: Q2 2026 in Review

Boothbay Fund Management increased its Ocular Therapeutix (OCUL) stake by 41% in Q2 2026, buying an estimated $487K and bringing the position to 186,356 shares worth $1.83M. The position accounts for 0.02% of the portfolio, ranked #768.

Boothbay Fund Management first reported a position in OCUL in Q2 2019 and has held it in 16 quarters since. The position peaked at $2.09M in Q2 2020. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Boothbay Fund Management held 186,356 shares of Ocular Therapeutix worth $1.83M as of Q2 2026.
  • Boothbay Fund Management bought 53,724 Ocular Therapeutix shares in Q2 2026, an estimated $487K.
  • Ocular Therapeutix made up 0.02% of Boothbay Fund Management's portfolio in Q2 2026, its #768 holding.
  • Boothbay Fund Management first reported a position in Ocular Therapeutix in Q2 2019 and has held it in 16 quarters since.
  • Boothbay Fund Management's Ocular Therapeutix position peaked at $2.09M in Q2 2020.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.